

Ryszard Międzybrodzki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1139233/publications.pdf>

Version: 2024-02-01

66
papers

3,310
citations

159585

30
h-index

155660

55
g-index

69
all docs

69
docs citations

69
times ranked

2764
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Aspects of Phage Therapy. <i>Advances in Virus Research</i> , 2012, 83, 73-121.	2.1	274
2	Transplantation of Autologous Olfactory Ensheathing Cells in Complete Human Spinal Cord Injury. <i>Cell Transplantation</i> , 2013, 22, 1591-1612.	2.5	238
3	Phage as a Modulator of Immune Responses. <i>Advances in Virus Research</i> , 2012, 83, 41-71.	2.1	206
4	Functional Regeneration of Supraspinal Connections in a Patient with Transected Spinal Cord following Transplantation of Bulbar Olfactory Ensheathing Cells with Peripheral Nerve Bridging. <i>Cell Transplantation</i> , 2014, 23, 1631-1655.	2.5	199
5	Bacteriophage translocation. <i>FEMS Immunology and Medical Microbiology</i> , 2006, 46, 313-319.	2.7	192
6	Phage Neutralization by Sera of Patients Receiving Phage Therapy. <i>Viral Immunology</i> , 2014, 27, 295-304.	1.3	179
7	Phage Therapy: Combating Infections with Potential for Evolving from Merely a Treatment for Complications to Targeting Diseases. <i>Frontiers in Microbiology</i> , 2016, 7, 1515.	3.5	120
8	Phages and immunomodulation. <i>Future Microbiology</i> , 2017, 12, 905-914.	2.0	117
9	Phage therapy: Current status and perspectives. <i>Medicinal Research Reviews</i> , 2020, 40, 459-463.	10.5	102
10	Phage Therapy: What Have We Learned?. <i>Viruses</i> , 2018, 10, 288.	3.3	101
11	Antibody Production in Response to Staphylococcal MS-1 Phage Cocktail in Patients Undergoing Phage Therapy. <i>Frontiers in Microbiology</i> , 2016, 7, 1681.	3.5	92
12	Factors determining phage stability/activity: challenges in practical phage application. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 583-606.	4.4	82
13	Effects of bacteriophages on free radical production and phagocytic functions. <i>Medical Microbiology and Immunology</i> , 2006, 195, 143-150.	4.8	81
14	Bacteriophage preparation inhibition of reactive oxygen species generation by endotoxin-stimulated polymorphonuclear leukocytes. <i>Virus Research</i> , 2008, 131, 233-242.	2.2	78
15	Antiphage activity of sera during phage therapy in relation to its outcome. <i>Future Microbiology</i> , 2017, 12, 109-117.	2.0	71
16	Phage-Phagocyte Interactions and Their Implications for Phage Application as Therapeutics. <i>Viruses</i> , 2017, 9, 150.	3.3	62
17	Phage Therapy: Towards a Successful Clinical Trial. <i>Antibiotics</i> , 2020, 9, 827.	3.7	59
18	A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. <i>Clinical and Experimental Medicine</i> , 2009, 9, 303-312.	3.6	53

#	ARTICLE	IF	CITATIONS
19	The perspectives of the application of phage therapy in chronic bacterial prostatitis. <i>FEMS Immunology and Medical Microbiology</i> , 2010, 60, 99-112.	2.7	51
20	Means to Facilitate the Overcoming of Gastric Juice Barrier by a Therapeutic Staphylococcal Bacteriophage A5/80. <i>Frontiers in Microbiology</i> , 2017, 08, 467.	3.5	50
21	Perspectives of Phage Therapy in Non-bacterial Infections. <i>Frontiers in Microbiology</i> , 2018, 9, 3306.	3.5	49
22	Phage Therapy in Poland – a Centennial Journey to the First Ethically Approved Treatment Facility in Europe. <i>Frontiers in Microbiology</i> , 2020, 11, 1056.	3.5	44
23	Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2007, 61, 461-5.	0.1	43
24	Treatment of recurrent urinary tract infections in a 60-year-old kidney transplant recipient. The use of phage therapy. <i>Transplant Infectious Disease</i> , 2021, 23, e13391.	1.7	42
25	Phages targeting infected tissues: novel approach to phage therapy. <i>Future Microbiology</i> , 2015, 10, 199-204.	2.0	40
26	The Effect of Bacteriophage Preparations on Intracellular Killing of Bacteria by Phagocytes. <i>Journal of Immunology Research</i> , 2015, 2015, 1-13.	2.2	39
27	<i>In Vivo</i> Studies on the Influence of Bacteriophage Preparations on the Autoimmune Inflammatory Process. <i>BioMed Research International</i> , 2017, 2017, 1-9.	1.9	39
28	Bacteriophages and antibiotic interactions in clinical practice: what we have learned so far. <i>Journal of Biomedical Science</i> , 2022, 29, 23.	7.0	39
29	Bacterial viruses against viruses pathogenic for man?. <i>Virus Research</i> , 2005, 110, 1-8.	2.2	38
30	The Potential of Phage Therapy in Sepsis. <i>Frontiers in Immunology</i> , 2017, 8, 1783.	4.8	35
31	The olfactory bulb and olfactory mucosa obtained from human cadaver donors as a source of olfactory ensheathing cells. <i>Glia</i> , 2006, 54, 557-565.	4.9	33
32	Prospects of Phage Application in the Treatment of Acne Caused by <i>Propionibacterium acnes</i> . <i>Frontiers in Microbiology</i> , 2017, 8, 164.	3.5	30
33	Phage Therapy: Beyond Antibacterial Action. <i>Frontiers in Medicine</i> , 2018, 5, 146.	2.6	27
34	Phages in the fight against COVID-19?. <i>Future Microbiology</i> , 2020, 15, 1095-1100.	2.0	26
35	Bacteriophages targeting intestinal epithelial cells: a potential novel form of immunotherapy. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 589-595.	5.4	24
36	Potential of Bacteriophages and Their Lysins in the Treatment of MRSA. <i>BioDrugs</i> , 2011, 25, 347-355.	4.6	23

#	ARTICLE	IF	CITATIONS
37	Phage-specific diverse effects of bacterial viruses on the immune system. <i>Future Microbiology</i> , 2019, 14, 1171-1174.	2.0	22
38	A3R Phage and <i>Staphylococcus aureus</i> Lysate Do Not Induce Neutrophil Degranulation. <i>Viruses</i> , 2017, 9, 36.	3.3	20
39	The fall and rise of phage therapy in modern medicine. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1115-1117.	3.1	19
40	Immune Response to Therapeutic <i>Staphylococcal</i> Bacteriophages in Mammals: Kinetics of Induction, Immunogenic Structural Proteins, Natural and Induced Antibodies. <i>Frontiers in Immunology</i> , 2021, 12, 639570.	4.8	19
41	Phage Therapy in Prostatitis: Recent Prospects. <i>Frontiers in Microbiology</i> , 2018, 9, 1434.	3.5	18
42	Phage Prevalence in the Human Urinary Tract—Current Knowledge and Therapeutic Implications. <i>Microorganisms</i> , 2020, 8, 1802.	3.6	16
43	Phage therapy of wound-associated infections. <i>Folia Microbiologica</i> , 2022, 67, 193-201.	2.3	15
44	Bacteriophage Interactions With Epithelial Cells: Therapeutic Implications. <i>Frontiers in Microbiology</i> , 2020, 11, 631161.	3.5	14
45	Phage therapy in allergic disorders?. <i>Experimental Biology and Medicine</i> , 2018, 243, 534-537.	2.4	13
46	Perspectives of Phage–Eukaryotic Cell Interactions to Control Epstein–Barr Virus Infections. <i>Frontiers in Microbiology</i> , 2018, 9, 630.	3.5	13
47	Current Updates from the Long-Standing Phage Research Centers in Georgia, Poland, and Russia. , 2018, , 1-31.		13
48	Therapeutic Perspectives and Mechanistic Insights of Phage Therapy in Allogeneic Transplantation. <i>Transplantation</i> , 2021, 105, 1449-1458.	1.0	13
49	Influence of Bacteriophage Preparations on Intracellular Killing of Bacteria by Human Phagocytes <i>in Vitro</i> . <i>Viral Immunology</i> , 2013, 26, 150-162.	1.3	12
50	Natural and Induced Antibodies Against Phages in Humans: Induction Kinetics and Immunogenicity for Structural Proteins of PB1-Related Phages. <i>Phage</i> , 2020, 1, 91-99.	1.7	12
51	A Thorough Synthesis of Phage Therapy Unit Activity in Poland—Its History, Milestones and International Recognition. <i>Viruses</i> , 2022, 14, 1170.	3.3	11
52	The Rationale for Using Bacteriophage to Treat and Prevent Periprosthetic Joint Infections. <i>Frontiers in Microbiology</i> , 2020, 11, 591021.	3.5	9
53	Low Immunogenicity of Intravesical Phage Therapy for Urogenital Tract Infections. <i>Antibiotics</i> , 2021, 10, 627.	3.7	9
54	Can phage therapy solve the problem of recalcitrant chronic rhinosinusitis?. <i>Future Microbiology</i> , 2017, 12, 1427-1442.	2.0	8

#	ARTICLE	IF	CITATIONS
55	“Phage Transplantation in Allotransplantation” Possible Treatment in Graft-Versus-Host Disease?. Frontiers in Immunology, 2018, 9, 941.	4.8	8
56	Potential for Phages in the Treatment of Bacterial Sexually Transmitted Infections. Antibiotics, 2021, 10, 1030.	3.7	8
57	Current Updates from the Long-Standing Phage Research Centers in Georgia, Poland, and Russia. , 2021, , 921-951.		8
58	Inhibitory Effects of Bacteriophage Preparations on Adenoviral Replication. Intervirology, 2019, 62, 37-44.	2.8	7
59	The effects of bacteriophages on the expression of genes involved in antimicrobial immunity*. Postepy Higieny I Medycyny Doswiadczalnej, 2019, 73, 414-420.	0.1	7
60	Sepsis, Phages, and COVID-19. Pathogens, 2020, 9, 844.	2.8	6
61	The contribution of phage therapy to medical knowledge. Journal of Global Antimicrobial Resistance, 2022, 28, 238-240.	2.2	6
62	Use of a Regression Model to Study Host-Genomic Determinants of Phage Susceptibility in MRSA. Antibiotics, 2018, 7, 9.	3.7	5
63	Phage Therapy in Orthopaedic Implant-Associated Infections. , 2019, , 189-211.		5
64	The effects of T4 and A5/80 phages on the expression of immunologically important genes in differentiated Caco-2 cells*. Postepy Higieny I Medycyny Doswiadczalnej, 2020, 74, 371-376.	0.1	5
65	Humoral Immune Response to Phage-Based Therapeutics. , 2019, , 123-143.		3
66	BronisÅława Fejgin (1883–1943): Forgotten Important Contributor to International Microbiology and Phage Therapy. Antibiotics, 2021, 10, 1353.	3.7	2